Thromboembolic disorders are a major cause of morbidity and mortality worldwide. Anticoagulation therapies represent the primary method for the treatment and/or prevention strategies for thromboembolic diseases. Currently available and approved anticoagulant agents, including warfarin and direct oral anticoagulants (DOACs), all

Patients with genetically associated elevated lipoprotein(a) [Lp(a)] levels are at greater risk for coronary artery disease, heart attack, stroke, and peripheral arterial disease. To date, there are no US FDA-approved drug therapies that are designed to target Lp(a) with the

Type 2 diabetes mellitus (T2DM) is one of the most diagnosed conditions in the United States. Antihyperglycemic medications are a mainstay in the treatment of T2DM to prevent complications such as cardiac and renal death.

Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels. When blood glucose levels are inadequately controlled or left untreated, the result is a variety of microvascular and macrovascular complications. To prevent these outcomes, many

Glaucoma is a disease affecting millions of people across the world every year. Medications designed to control or decrease intraocular pressure are the gold standard for treatment and often belong to a class of medications called prostaglandin analogues. These topical

Icosapent ethyl (IPE) was the first fish oil product the US Food and Drug Administration (FDA) approved to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) in adults. IPE is an esterified version of eicosapentaenoic acid (EPA) and acts as

Patients with arrythmias are at an increased risk of heart-related comorbidities and complications. Specifically, patients with paroxysmal supraventricular tachycardia (PSVT), a type of arrythmia, are at increased risk of lightheadedness or shortness of breath, due to the increased rate of

Levels of free myeloperoxidase (MPO), a cardiovascular risk marker, have been reported to decline with standard care. Whether such declines signify decreased risk of mortality remains unknown.

Clareon® Vivity®, intraocular lenses (IOLs) feature a hydrophobic acrylic biomaterial and smooth surface that contribute to improved optical lens clarity. Clareon® IOLs illustrated excellent mechanical stability, however no studies have been performed assessing the effects of decentration and tilt of

Patients with hypertension are at an increased risk of cardiovascular disease and death. Resistant hypertension, or hypertension that is unsuccessfully treated with multiple antihypertensive medications, further exacerbates the complications and negative outcomes for patients. A new pathway, via aldosterone synthesis

Objective: This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of travoprost, intracameral implant, a treatment for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Data Sources: A literature search

IMPORTANCE There is a need for additional treatment options for people with type 2 diabetes treated with insulin. Given the limited data on the use of automated insulin delivery (AID) systems in type 2 diabetes, studies evaluating their safety and efficacy